BD gains exclusive rights to Cygnus' GlucoWatch non-invasive monitor for $20 mil..
This article was originally published in The Gray Sheet
Executive Summary
BECTON DICKINSON PAYS $20 MIL. FOR MARKETING RIGHTS TO CYGNUS' GLUCOWATCH non-invasive blood glucose meter under an agreement announced Feb. 14. BD's $20 mil. commitment consists of an up-front equity investment and milestone payments based on progress toward bringing the device to market. In return, BD is gaining worldwide, exclusive rights to the development-stage GlucoWatch except for Japan and Korea.